Cell Harvesting Market Report 2026

The cell harvesting market size has grown strongly in recent years. It will grow from $11.51 billion in 2025 to $12.37 billion in 2026 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to increasing monoclonal antibody production, expansion of biopharmaceutical manufacturing capacity, rising adoption of cell-based therapeutics, increased focus on downstream process efficiency, growing use of centrifugation-based harvesting.

The cell harvesting market size is expected to see strong growth in the next few years. It will grow to $16.22 billion in 2030 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to increasing investments in biologics manufacturing, rising demand for scalable cell processing solutions, growing adoption of continuous bioprocessing, increasing use of single-use technologies, expansion of advanced cell therapy pipelines. Major trends in the forecast period include increasing adoption of automated cell harvesting systems, rising demand for high-throughput cell processing, growing use of closed-system harvesting solutions, expansion of microfluidic harvesting technologies, enhanced focus on process consistency and yield optimization.

The increasing prevalence of cancer is anticipated to drive the growth of the cell harvesting market in the coming years. Cancer encompasses a group of diseases marked by the uncontrolled and abnormal proliferation of cells, often resulting in the formation of a tumor or mass. The rising incidence of cancer is boosting demand for cell harvesting, as it plays a vital role in research activities, diagnostic uses, therapeutic development, and in advancing the overall understanding of cancer biology. This growing reliance on cell harvesting across multiple cancer-related research and clinical applications is contributing significantly to market expansion. For instance, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, an estimated 165,000 individuals were newly diagnosed with cancer in Australia in 2023, representing more than 450 new cases per day, with males accounting for approximately 55% of these diagnoses. Therefore, the growing burden of cancer is fueling the expansion of the cell harvesting market.

Major companies operating in the cell harvesting market are concentrating on the development of advanced automated platforms to improve efficiency, throughput, and consistency in single-cell isolation and analysis. Automated cell processing systems combine microfluidics, robotics, and imaging technologies to optimize workflows from cell sorting through recovery. For instance, in March 2025, Sphere Fluidics, a UK-based life sciences technology company, introduced the Cyto-Mine Chroma platform and announced an Early Access Program. This platform supports high-throughput single-cell screening and harvesting with enhanced accuracy and speed, enabling research and biomanufacturing applications in areas such as drug discovery, cell line development, and precision medicine.

In January 2024, AstraZeneca plc, a UK-based pharmaceutical company, acquired Gracell Biotechnologies for $1 billion. Through this acquisition, AstraZeneca aims to strengthen its cell therapy portfolio and utilize innovative manufacturing technologies to develop leading treatments for hematologic cancers and autoimmune disorders. Gracell Biotechnologies is a China-based biopharmaceutical firm focused on developing cell therapies for cancer and autoimmune diseases.

Major companies operating in the cell harvesting market are Sartorius AG, Danaher Corporation, Merck & Co. Inc., Pall Corporation, Thermo Fisher Scientific Inc., GE Healthcare, Esco Lifesciences Group, CESCO Bioengineering Co. Ltd., Alfa Laval Corporate AB, GEA Group Aktiengesellschaft, SPX Flow Inc., Parker Hannifin Corporation, PBS Biotech Inc., Lonza Group AG, Becton Dickinson and Company, Bio‑Rad Laboratories Inc., STEMCELL Technologies Inc., Corning Incorporated, Nikon Corporation (Healthcare Business Unit), PromoCell GmbH, Flottweg SE, Repligen Corporation.

North America was the largest region in the cell harvesting market share in 2025. The regions covered in the cell harvesting market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell harvesting market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the cell harvesting market by increasing costs of imported centrifuges, filtration membranes, robotic systems, and precision-engineered components used in manual and automated harvesting platforms. Biopharmaceutical manufacturers in North America and Europe are most affected due to reliance on imported high-end processing equipment, while Asia-Pacific faces higher capital expenditure for expanding biologics capacity. These tariffs are increasing operational costs and extending procurement timelines for production-scale systems. However, they are also encouraging domestic manufacturing of bioprocessing equipment, localized assembly of harvesting systems, and increased innovation in cost-efficient cell harvesting technologies.

The cell harvesting market research report is one of a series of new reports that provides cell harvesting market statistics, including cell harvesting industry global market size, regional shares, competitors with a cell harvesting market share, detailed cell harvesting market segments, market trends and opportunities, and any further data you may need to thrive in the cell harvesting industry. This cell harvesting market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cell harvesting is a critical unit operation that involves separating cells, cell debris, and other soluble and insoluble impurities that could interfere with downstream chromatographic separation processes. It serves as a vital step connecting upstream monoclonal antibody production with downstream purification.

The main types of cell harvesting include manual cell harvesters and automated cell harvesters. Manual cell harvesters refer to medical devices used to collect cells from a cell culture medium without the use of automated instruments, relying instead on manual collection methods. These are utilized by end users such as biotechnology and biopharmaceutical companies, research institutes, and others, and are supplied through distribution channels including retail sales and direct tenders.

The cell harvesting includes revenues earned by entities by centrifugation, filtration, and microfiltration. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.